Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia.
10.3760/cma.j.issn.0253-2727.2023.10.001
- Author:
Meng Yi DU
1
;
Yan Qiang ZHANG
1
;
Dan Ying LIAO
1
;
Wei XIE
1
;
Wei XIONG
1
;
Heng MEI
1
;
Yu HU
1
Author Information
1. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
- Publication Type:Journal Article
- Keywords:
B cell acute lymphoblastic leukemia;
Chimeric antigen receptor T cell;
Humanized;
Long-term follow-up
- MeSH:
Animals;
Humans;
Mice;
Antigens, CD19;
Burkitt Lymphoma/drug therapy*;
Cell- and Tissue-Based Therapy;
Follow-Up Studies;
Immunotherapy, Adoptive;
Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy*;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*;
Receptors, Chimeric Antigen
- From:
Chinese Journal of Hematology
2023;44(10):793-799
- CountryChina
- Language:Chinese
-
Abstract:
Objective: Murine CD19 chimeric antigen receptor T-cell (CAR-T) products have been approved for the treatment of refractory/relapsed (R/R) B-cell acute lymphocytic leukemia (B-ALL) ; moreover, humanized products are also undergoing clinical trials. This study aimed to explore the differences in safety and short- and long-term follow-up efficacy between humanized and murine CD19 CAR-T-cells for treating relapsed and refractory B-ALL. Methods: Clinical data of 80 patients with R/R B-ALL treated with CD19-targeted CAR-T-cells at the Union Hospital of Tongji Medical College of Huazhong University of Science and Technology between May 2016 and March 2023 were analyzed, which included 31 patients with murine CAR-T and 49 with humanized products. Results: The proportion of patients with cytokine-release syndrome (CRS) in the murine and humanized groups was 63.1% and 65.3%, respectively. Moreover, a higher proportion of patients suffered from severe CRS in the murine group than in the humanized CAR-T group (19.4% vs 8.2%, P=0.174). Furthermore, one patient per group died of grade 5 CRS. The incidence of grade 1-2 immune effector cell-associated neurotoxicity syndrome (ICANS) was 12.9% and 6.1%, respectively; severe ICANS were not observed. Among patients receiving murine CAR-T-cells, an overall response (OR) was observed in 74.2%. Conversely, the OR rate of patients receiving humanized CAR-T-cells was 87.8%. During the median follow-up time of 10.5 months, the median recurrence-free survival (RFS) of patients with murine CAR-T-cells was 12 months, which was as long as that of patients with humanized CAR-T-cells. The median overall survival (OS) were not reached in both groups. Of the 45 patients with a bone marrow burden over 20% at baseline, humanized CAR-T therapy was associated with a significantly improved RFS (43.25% vs 33.33%, P=0.027). Bridging transplantation was an independent factor in prolonging OS (χ(2)=8.017, P=0.005) and PFS (χ(2)=6.584, P=0.010). Common risk factors, such as age, high proportion of bone marrow blasts, and BCR-ABL fusion gene expression, had no significant effect on patients' long-term follow-up outcomes. Three patients reached complete remission after reinfusion of humanized CAR-T-cells. However, one patient relapsed one month after his second infusion of murine CAR-T-cells. Conclusions: The results indicate that humanized CAR-T therapy showed durable efficacy in patients with a higher tumor burden in the bone marrow without any influence on safety. Moreover, it could overcome immunogenicity-induced CAR-T resistance, providing treatment options for patients who were not treated successfully with CAR-T therapies.
